Stockscreener 앱 받기
0.6423
5.30%
0.0323
시간 외 거래:
.62
-0.0223
-3.47%
전일 마감가:
$0.61
열려 있는:
$0.6
하루 거래량:
499.13K
Relative Volume:
0.20
시가총액:
$25.45M
수익:
$1.04M
순이익/손실:
$-67.50M
주가수익비율:
-0.3341
EPS:
-1.9222
순현금흐름:
$-60.67M
1주 성능:
+1.82%
1개월 성능:
+8.44%
6개월 성능:
-78.45%
1년 성능:
-76.39%
1일 변동 폭
$0.5901
$0.6489
1주일 범위
$0.5901
$0.67
52주 변동 폭
$0.43
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
명칭
Vistagen Therapeutics Inc
전화
650-577-3600
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.6423 | 24.17M | 1.04M | -67.50M | -60.67M | -1.9222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2025-12-17 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-12-17 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-07-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 개시 | Jefferies | Buy |
| 2021-01-04 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2018-02-08 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-28 | 개시 | Maxim Group | Buy |
모두보기
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
VistaGen at Stifel CNS Forum: Strategic Insights on Fasedienol By Investing.com - Investing.com Canada
Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN)March 16, 2026 Deadline to JoinContact Levi & Korsinsky - PR Newswire
VistaGen Showcases Intranasal Pherine Pipeline in New Presentation - TipRanks
Vistagen (NASDAQ: VTGN) details pherine CNS pipeline in new presentation - Stock Titan
Bronstein, Gewirtz & Grossman LLC Urges Vistagen - GlobeNewswire
CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline Tonight - The Daily Tribune News
VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit - Financial Times
Vistagen Therapeutics, Inc. (VTGN) Eyes Breakthrough with Phase 3 Social Anxiety Trial - MSN
VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. ... - Black Hills Pioneer
VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - GlobeNewswire Inc.
VTGN UPCOMING DEADLINE ON MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit (2026-03-14) - Seeking Alpha
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 16, 2026 in Vistagen LawsuitVTGN - PR Newswire
VTGN DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors ... - Caledonian Record
VTGN DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages - GlobeNewswire
VTGN Shareholder Alert: Vistagen Therapeutics, Inc. - GlobeNewswire
2026-03-13 | VTGN DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Vistagen Therapeutics, Inc. Investors to Join the Class Action Lawsuit Today | NDAQ:VTGN | Press Release - Stockhouse
Evotec, Vistagen lay off staff; Immutep shares collapse on study failure - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesVTGN - Sahm
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Lelezard
Holzer & Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the Vistagen Therapeutics, Inc. Securities Class Action - marketscreener.com
Holzer & Holzer, LLC Reminds VTGN Investors of the March - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
VTGN INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - ChartMill
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER - GlobeNewswire
VistaGen Announces Workforce Reduction to Extend Cash Runway - The Globe and Mail
VTGN SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - Lelezard
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, I - GuruFocus
Vistagen Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsVTGN - cnhinews.com
Layoff Tracker: Vistagen, Evotec, Reckitt Benckiser Downsize, Collectively Affecting Hundreds - BioSpace
Does Vistagen Therapeutics Inc. stock trade at a discount to peersForecast Cut & Reliable Price Action Trade Plans - mfd.ru
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, - GlobeNewswire
Vistagen Therapeutics, Inc. Files Form 8-K with SEC: Company Information, Stock Details, and Compliance Disclosures (March 2026) - Minichart
LEVI & KORSINSKY, LLP ADVISORY TO INSTITUTIONAL INVESTORS: CLASS ACTION AGAINST VISTAGEN THERAPEUTICS MAY IMPACT PORTFOLIO HOLDINGS - Morningstar
Aug Highlights: Will Vistagen Therapeutics Inc outperform during market ralliesIPO Watch & Long Hold Capital Preservation Tips - baoquankhu1.vn
Vistagen Therapeutics reduces workforce by 20 percent to manage costs - Investing.com South Africa
Vistagen Therapeutics (MEX:VTGN) NonCurrent Deferred Revenue : MXN3.17 Mil (As of Dec. 2025) - GuruFocus
Vistagen Therapeutics Implements 20% Workforce Reduction - TradingView
Vistagen Therapeutics cuts ~20% of workforce, expects PALISADE-4 topline H1 2026 and cash into 2027 - TradingView
Vistagen (VTGN) slashes workforce 20% to focus on PALISADE-4 Phase 3 trial - Stock Titan
VTGN DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages - GlobeNewswire
VTGN INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline on March 16, 2026 - marketscreener.com
Contact The Gross Law Firm by March 16, 2026 Deadline to Join Class Action Against Vistagen Therapeutics, Inc.(VTGN) - PR Newswire
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors - GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Vistagen Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi ... - Bluefield Daily Telegraph
Vistagen Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
VTGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Vistagen (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - TMX Newsfile
VTGN (Vistagen Therapeutics) ROC (Joel Greenblatt) % : -5,196.68% (As of Dec. 2025) - GuruFocus
Vistagen Therapeutics (MEX:VTGN) Future 3-5Y EPS without NR - GuruFocus
Vistagen Therapeutics Inc (VTGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):